Peter DeMuth

Peter DeMuth

Company: Elicio Therapeutics

Job title: Chief Scientific Officer


Lymph-Node Targeted Peptide Vaccination Promotes mKRAS-Specific T Cell Immunity & Enhances TCR-T Cell Therapy Against Solid Tumors 12:30 pm

The AMP platform enables enhanced lymph node delivery of peptide immunogens and molecular adjuvants to potently stimulate T cell immunity AMP-vaccination promotes expansion and functional enhancement of endogenous and adoptively transferred mKRAS-specific T cells in vitro and in vivo AMP-vaccine combination with TCR-T cell therapy promotes anti-tumor efficacy in vivoRead more

day: Day One Track A

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.